The Effect of Granulocyte-Colony Stimulating Factor in Remission Induction Chemotherapy of Acute Myelogenous Leukemia.
- Author:
Jae Hyuk CHOI
1
;
Gu LEE
;
Hyun Ah OH
;
Hee Jung KWANG
;
Jae Lyun LEE
;
Kyung Hee LEE
;
Myung Soo HYUN
;
Hun Mo RYU
Author Information
1. Department of Internal Medicine, College of Medicine, Yeungnam University, Daegu, Korea. hms@medical.yeungnam.ac.kr
- Publication Type:Original Article
- Keywords:
G-CSF;
Neutropenia;
Acute myelogenous leukemia
- MeSH:
Anti-Bacterial Agents;
Colony-Stimulating Factors;
Drug Therapy*;
Granulocyte Colony-Stimulating Factor;
Humans;
Incidence;
Leukemia, Myeloid, Acute*;
Neutropenia;
Neutrophils;
Remission Induction*
- From:Korean Journal of Hematology
2002;37(1):17-23
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Colony stimulating factors have been shown to accelerate recovery from severe neutropenia after intensive chemotherapy. To prove its clinical effectiveness, we conducted this study of administration of G- CSF in acute myelogenous leukemia after remission induction chemotherapy. METHODS: Thirty six patients with acute myelogenous leukemia were assigned to one of two groups (21 to G-CSF treated group, 15 to control group) after remission induction che motherapy administration. Treatment with G-CSF (lenograstim, 200ng/m2/d) was started 5 days after the end of chemotherapy and continued until the neutrophil count rose above 1,500/mm3. RESULTS: Treatment with G-CSF shortened neutropenic period after chemotherapy. The median time to recovery to neutrophil counts more than 500/mm3 from the end of chemotherapy was 19 days in G-CSF treated group and 25 days in control group. The incidence of infection was 19 cases in G-CSF treated group and 13 cases in control group and febrile periods were 12 days in G-CSF treated group and 15 days in control group, but there were no statistically significant differences. The duration of antibiotics treatment in G-CSF treated group was shorter than that of control group. There was no evidence that G-CSF could increase remission duration and overall survival. CONCLUSION: Recombinant G-CSF is safe and useful in patients after intensive chemotherapy, accelerating neutrophil recovery and thereby reducing the duration of antibiotics administration.
